Abstract 255P
Background
Breast cancer by far has risen to the most common cancer overall. The estrogen receptor (ER) is expressed in 75% of breast cancers in general. Tamoxifen (TAM) has been approved for reducing relapse by approximately 40%-50% in ER positive metastatic breast cancer. There are still approximately 40% patients showing primary or secondary TAM drug resistance to endocrine therapies, leading to relapse and metastasis. It’s urgent to develop an approach for evaluation of prognosis and drug resistance at an early stage. Here comes Propreseer applied in TAM-resistance breast cancer.
Methods
We presented a prognostic model called Propreseer to facilitate the routine of large-scale long-running prognostic analysis. Public databases like Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA), and bio-statistics were involved, and 737 cases with breast cancer and 584 cases with ovarian cancer were considered. By Propreseer, the patients were then divided into high-risk group and low-risk group according to the risk value output, and the correlations among the risk value, clinical indexes and prognosis were analyzed.
Results
By Propreseer, six differentially expressed lncRNA (ENG00000230440, ENG00000231128, ENG00000232986, ENG00000249346, ENG00000253898, and ENG00000258412) were identified (all P<0.05). The mortality rate in high-risk group was higher than that in low-risk group(P<0.01), indicating the overall survival was worse in high-risk group. The overall survival in high-risk group was shorter than that in low-risk group(P<0.01), presenting consistency both in training set (P =7*10-7) and validation set (P =0.008). Area under the curve (AUC) was 0.750 from three-year track, and 0.680 from five-year track, confirming that Propreseer had certain accuracy. Risk value remained an independent prognostic factor (all P<0.001), and was significantly correlated with TNM stage (P<0.05) and lymph node metastasis (P<0.05).
Conclusions
Propreseer had certain value in prognostic for TAM-resistance breast cancer, providing new target molecules for further use in combination therapies, molecular mechanisms and potential drug targets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.